Sells automated microbial-quality testing systems, consumables and related services to pharmaceutical manufacturers producing biologics, vaccines, cell and gene therapies, and sterile injectables.
10-K for FY2025, filed Mar 12, 2026
Customers buy systems, software and consumables; payment is typically due 30 to 90 days after shipment or delivery. Service revenue comes from validation, installation and field work, plus maintenance contracts, with those services delivered at milestones or over the contract term.
10-K for FY2025, filed Mar 12, 2026The Company derives product revenue primarily from the sale of its systems, optional LIMS connection software, which facilitates the…View ↗
Transfer of control is generally at shipment or delivery, depending on contractual terms, and occurs when title and risk of loss transfers…View ↗
The Company derives service revenue primarily from validation services, service contracts and field service (including installation). The…View ↗
Payment terms for customer orders are typically between 30 to 90 days after the shipment or delivery of the product and apply to all…View ↗
10-K for FY2025, filed Mar 12, 2026
FY2025 revenue by product or service ↗$33.6M
10-K for FY2025, filed Mar 12, 2026
$33.6M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2025, filed Mar 12, 2026 |
70%
FY2022: 65%
|
Product, FY2025
$23.4M Sources
|
Sold outright |
|
Service
|
30%
FY2022: 35%
|
Service, FY2025
$10.2M Sources
|
Pharmaceutical manufacturers buy directly from the company’s sales teams in North America, Europe and Asia-Pacific, while distributors support some territories. MilliporeSigma has co-exclusive rights to sell systems and consumables for industrial quality-control uses.
10-K for FY2025, filed Mar 12, 2026
No. It lost $47.1M in FY2025.
10-Q for Q2 FY2026, filed Aug 7, 2026
−$12.9MView ↗
10-Q for Q2 FY2026, filed Aug 7, 2026
Open tableView ↗
Growing. Revenue grew 45% in 4 years, from $23.2M in FY2021 to $33.6M in FY2025, about 10% a year.
Broader sales channels
The older report describes direct sales in North America and Europe; the latest report also describes direct sales in Asia-Pacific and distributors supporting certain territories.
10-K for FY2022, filed Mar 10, 2023 10-K for FY2025, filed Mar 12, 2026We employ direct commercial and service teams that drive the adoption of our products globally. We create a superior user experience from…View ↗
We employ direct commercial and service teams that drive the adoption of our products globally. We create a superior user experience from…View ↗
Industrial quality-control markets
The older report describes the platform for pharmaceutical manufacturing. The latest report adds a co-exclusive distribution arrangement covering industrial quality control in medical devices, personal care, cosmetics, and food and beverage.
10-K for FY2022, filed Mar 10, 2023 10-K for FY2025, filed Mar 12, 2026We are an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient…View ↗
In February 2025, we entered into a Distribution and Collaboration Agreement (the “Distribution Agreement”) with Millipore S.A.S., a…View ↗
Loading...